10073-CBMS-6 CURCUMIN ANALOG B EXHIBIT ANTI-TUMOR ACTIVITY AGAINST GLIOBLASTOMAAT LOWER CONCENTRATIONS THAN CURCUMIN
Kyoko Inai, Toshihide Hamabe-Horiike, Masaya Ono, Sonoka Iwashimizu, Ryo Ito, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto · 2023
Read 10073-CBMS-6 CURCUMIN ANALOG B EXHIBIT ANTI-TUMOR ACTIVITY AGAINST GLIOBLASTOMAAT LOWER CONCENTRATIONS THAN CURCUMIN by Kyoko Inai, Toshihide Hamabe-Horiike, Masaya Ono, Sonoka Iwashimizu, Ryo Ito, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710655.txt.
Description
Inai and nine co-authors tested a curcumin relative against brain tumors in this conference report from twenty twenty-three. Glioblastoma resists surgery and the standard drug, so new agents are hunted widely. The team compared curcumin and its analog, Compound B, on two human glioblastoma cell lines. A standard viability assay measured the doses needed to halve cell growth.
Compound B worked at far lower doses than curcumin in both lines. Healthy rat astrocytes survived those doses unharmed. The compound froze the cell cycle before division and triggered programmed cell death. Two genes driving that cycle step fell in expression. The authors call for animal studies toward a new glioblastoma drug.
Catalog record
| CREATOR | Kyoko Inai, Toshihide Hamabe-Horiike, Masaya Ono, Sonoka Iwashimizu, Ryo Ito, Yoichi Sunagawa, Yasufumi Katanasaka, Yoshiki Arakawa, Koji Hasegawa, Tatsuya Morimoto |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |